Research summary, original research, 2014

Lightweight bilayer barium sulfate-bismuth oxide composite thyroid collars for superior radiation protection in fluoroscopy-guided interventions: a prospective randomized controlled trial

Uthoff H, Benenati MJ, Katzen BT, Peña C, Gandhi R, Staub D, et al.. Radiology. 2014

Read the original paper

In plain language

In a single-center randomized trial of operators during vascular interventions, lighter bismuth-barium composite thyroid collars blocked more measured radiation than standard lead collars (about 91% vs 72%) and were rated more comfortable. Dose was measured, not thyroid disease.

At a glance

Type of study
Original research, Randomized trial
Who was studied
Interventional radiologists
Size
n = 256 thyroid collar measurements (144 procedures)
Summary based on
the abstract

What it found

  • Bilayer barium sulfate-bismuth oxide (XPF) thyroid collars reduced operator thyroid-region dose more than standard 0.5-mm lead-equivalent collars.

    Key figures: 90.7% vs 72.4%; adjusted mean difference 17.9% (95% confidence interval (CI): 7.7%, 28.1%; P < .001)

  • XPF collars were almost half the weight of standard collars.

    Key figures: 47.6% lighter; 133 g ± 14 vs 254 g ± 44; P < .001

  • Operators wearing XPF collars were much more likely to report high comfort.

    Key figures: Odds ratio (OR) 7.6 (95% CI: 3.0, 19.2; P < .001) for VAS >90

  • Patient and procedure characteristics, including fluoroscopy time and dose-area product, did not differ between groups.

Limits to keep in mind

Single-center trial of vascular interventions with dose analysis available in only 117 of 256 data sets; outcome is dosimeter dose rather than health effects, and comfort was self-rated by unblinded operators.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.